NCT02025985: A trial that was reported late by Karyopharm Therapeutics Inc
This trial has reported, although it was 1045 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT02025985 |
|---|---|
| Title | A Phase II, Open-label Study of Efficacy and Safety of the Selective Inhibitor of Nuclear Export/SINE™ Compound KPT-330 (Selinexor) in Patients With Advanced Gynaecologic Malignancies |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | April 9, 2014 |
| Completion date | Jan. 24, 2017 |
| Required reporting date | Jan. 24, 2018, midnight |
| Actual reporting date | Dec. 4, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 1045 |